NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. (OTCBB: LEVP.OB) today announced that it has formally submitted its complete response to the U.S. Food and Drug Administration’s (FDA) complete response (or “approvable”) letter for the Company’s lead product candidate, Cinryze™ (C1 inhibitor). Lev is seeking marketing approval for Cinryze™ for both the acute and prophylactic treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency.
